Epsametostat

艾普美妥司他

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameEpsametostat
Drug Alias NameHH-2853
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone-lysine N-methyltransferase EZH1 inhibitorsHistone-lysine N-methyltransferase EZH2 inhibitors
TargetsHistone-lysine N-methyltransferase EZH2Histone-lysine N-methyltransferase EZH1
Therapy Area/IndicationsEpithelioid SarcomaSolid tumoursSarcoma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland ChinaJapan
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesShangHai HaiHe Biopharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHaihe Biopharma (HK) LtdShangHai HaiHe Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsEpithelioid SarcomaSolid tumoursSarcoma +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A